Biotech news
Pharma
Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed. 16 March 2021
Biotech
China must safeguard IP in the seed industry to ensure innovation within the sector, the group chairman of Chinese multinational Sinochem, Frank Ning, has warned. 11 March 2021
Biotech
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community. 9 March 2021
Pharma
On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK. 8 March 2021
Pharma
Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China. 2 March 2021
Biotech
Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes. 2 March 2021
Biotech
The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally. 1 March 2021
Biotech
Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes. 25 February 2021
Biotech
The University of Texas has failed to persuade the US Court of Appeals for the Federal Circuit to review a ruling that prevented it from using sovereign immunity to protect its cancer vaccine patents from inter partes reviews. 18 February 2021
Americas
The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office. 9 February 2021